Linked Life Data

2962075

Source:http://linkedlifedata.com/resource/pubmed/id/2962075

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1988-1-25
pubmed:abstractText
Although our information on the pharmacological effects of ipratropium bromide in childhood has increased, its role has yet largely to be defined. Studies indicate that in children over the age of 2 to 3 years the optimal dose is probably 250 micrograms. For children under this age the maximum dose should probably be 125 micrograms delivered as a nebulized solution. In pre-term babies doses in excess of 20 micrograms are likely to produce side effects. Studies indicate that ipratropium bromide is effective in some pre-term babies who have airways obstruction following positive pressure ventilation but it can be a useful agent in the first 18 months of life, when beta 2-stimulants are rarely effective. Approximately 40% of children with recurrent attacks of airways obstruction obtain very useful benefit. Its place in the management of older children with asthma has yet to be defined. Although there have been a number of recent studies on the role of ipratropium bromide in childhood, information remains relatively sparse.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0032-5473
pubmed:author
pubmed:issnType
Print
pubmed:volume
63 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
53-6
pubmed:dateRevised
2010-12-21
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Ipratropium bromide and airways obstruction in childhood.
pubmed:affiliation
Department of Paediatric Respiratory Medicine, University Hospital, Queen's Medical Centre, Nottingham, UK.
pubmed:publicationType
Journal Article, Review